Noradrenalin Aguettant (Noradrenaline Tartrate)

Noradrenaline tartrate acts as an agonist at α1‑adrenergic receptors, causing strong vasoconstriction that raises systemic vascular resistance. It also stimulates β1‑adrenergic receptors in the heart, providing a modest increase in heart rate and contractility, together supporting blood pressure and cardiac output during shock.

The dosage of Noradrenalin Aguettant is individualized by the prescribing clinician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. Dosing is typically expressed as a continuous intravenous infusion that is titrated to achieve the desired circulatory effect.

Safety data for noradrenaline tartrate in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is prescribed under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Noradrenalin Aguettant is a first‑line vasopressor due to its potent α1‑mediated vasoconstriction and modest β1 activity, offering a balanced increase in blood pressure and cardiac output. Compared with agents such as dopamine or phenylephrine, noradrenaline provides more predictable hemodynamic control with fewer tachyarrhythmic effects.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and potency.

Noradrenalin Aguettant is supplied as an intravenous solution and is administered via continuous infusion through a central or peripheral venous line. The infusion rate is adjusted by the clinician to reach the target blood pressure while monitoring the patient’s response.

Serious risks include severe hypertension, cardiac arrhythmias, myocardial ischemia, tissue necrosis from extravasation, and pulmonary edema. Continuous hemodynamic monitoring and prompt management of any adverse events are essential during therapy.

Patients with known hypersensitivity to noradrenaline or any component of the formulation should not receive the product. Caution is also advised in individuals with severe peripheral vascular disease, uncontrolled tachyarrhythmias, or those receiving MAO inhibitors, unless the benefits clearly outweigh the risks.